Targeting AKT in HER2-Negative BC

CME

Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 27, 2023

Expiration: July 26, 2024

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1
Course Completed

For those providing patient care, how many patients with breast cancer do you provide care for in a typical week?

All of the following genomic alterations support the use of AKT inhibitors in breast cancer EXCEPT:

Which of the following adverse events (AEs) commonly associated with the addition of capivasertib to endocrine therapy would be important to discuss with your patient with HR-positive metastatic breast cancer who is considering new treatment alternatives?

The CAPItello-291 trial compared the oral AKT inhibitor capivasertib plus fulvestrant vs placebo plus fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer resistant to aromatase inhibitor (AI) therapy. Which of the following PFS outcomes was reported with capivasertib plus fulvestrant vs the control arm in this study?